Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
← catalyst calendarNCT07022483 · readout in 2,043 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With AstraZeneca.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
710estimated
Sites
75
Countries
Argentina, Chile, China +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-30 | actual | When the study began enrolling |
| Primary completion | 2032-03-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-03-23 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Endometrial Cancer
Interventions
- Drug: Trastuzumab Deruxtecan — also filed as T-DXd, ENHERTU®
- Drug: Chemotherapy
Primary outcome
what the primary-completion date above is the date OFDisease-Free Survival as Assessed by Blinded Independent Central Review or by Histopathologic Confirmation of Disease Recurrence per Local Assessment
measured From randomization to the first documented local regional recurrence, distant metastasis, or death due to any cause, whichever occurs first, up to approximately 51 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed